Bluefin Capital Management LLC Makes New Investment in Inhibrx Biosciences, Inc. $INBX

Bluefin Capital Management LLC acquired a new position in Inhibrx Biosciences, Inc. (NASDAQ:INBX) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,408 shares of the company’s stock, valued at approximately $160,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in INBX. State of Wyoming bought a new stake in shares of Inhibrx Biosciences during the fourth quarter valued at approximately $83,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Inhibrx Biosciences during the fourth quarter valued at approximately $102,000. GAMMA Investing LLC increased its position in shares of Inhibrx Biosciences by 9,834.8% during the first quarter. GAMMA Investing LLC now owns 6,855 shares of the company’s stock valued at $960,000 after acquiring an additional 6,786 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Inhibrx Biosciences during the fourth quarter valued at approximately $128,000. Finally, Bank of America Corp DE bought a new stake in shares of Inhibrx Biosciences during the fourth quarter valued at approximately $191,000. Institutional investors own 82.46% of the company’s stock.

Inhibrx Biosciences Stock Up 1.6%

INBX opened at $29.58 on Wednesday. The company has a quick ratio of 4.98, a current ratio of 4.98 and a debt-to-equity ratio of 1.45. The firm has a 50 day moving average price of $23.42 and a 200-day moving average price of $16.72. Inhibrx Biosciences, Inc. has a twelve month low of $10.81 and a twelve month high of $30.23. The stock has a market capitalization of $428.47 million, a price-to-earnings ratio of -2.80 and a beta of 0.31.

Inhibrx Biosciences (NASDAQ:INBX) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($1.85) earnings per share for the quarter, beating the consensus estimate of ($2.92) by $1.07. The company had revenue of $1.30 million for the quarter. Equities research analysts forecast that Inhibrx Biosciences, Inc. will post 104.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on INBX. JMP Securities reissued a “market perform” rating on shares of Inhibrx Biosciences in a research report on Friday, August 22nd. Wall Street Zen raised shares of Inhibrx Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 17th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Inhibrx Biosciences Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.